Similarly, in analyses stratified by the number of risk factors present out of the six IMDC risk factors, there was a significant survival benefit of cytoreductive nephrectomy only among patients with three or fewer factors (incremental benefit of 6-10 months, P less than .005 for each).
The impact of overall tumor burden and the size of the primary tumor were not considered in this analysis but will be in subsequent analyses, according to Dr. Heng.
He disclosed that he is a consultant/adviser to Aveo, Bayer, Bristol-Myers Squibb, Novartis, and Pfizer.